Ticagrelor drugs are primarily used in the treatment of cardiovascular disorders and other heart conditions, including diseased vessels, structural problems, and blood clots. In acute coronary syndrome, the combination of ticagrelor and aspirin is reported to have reduced the rate of vascular deaths and myocardial infarctions. As a result, ticagrelor drugs garner a vast market prominence and its market witness’s pervasive growth.
Increasing occurrences of cardiovascular disorders is a dominant driving force behind the growth of the market. Besides, the rise in the geriatric popula0074ion has a direct impact on the growth of the market. According to a leading research firm - Market Research Future (MRFR), the global Ticagrelor Market is relied upon to enroll a CAGR of 6.40% and is expected to arrive at USD 2.94 Billion by 2030. Additionally, increasing occurrences of obesity are encouraging the market demand, fuelling the cardiovascular patient pool. Also, growing numbers of drug manufacturers are driving the growth of the market, bringing novel medications in the market. Substantial investments transpired into RD activities driven by improving economic conditions provide impetus to the growth of the market.
Major Players:
Leading the global Ticagrelor Market Players include Eli Lilly, AstraZeneca, Boehringer, Pfizer, Ingelheim, Amgen, Roche, Merck, GSK, Ingelheim Pfizer, Alexion, Boehringer, Amgen
Global Ticagrelor Market – Segments
The report is segmented into five market dynamics to widen the scope of understanding,
- By Dosage: 90 Mg and 60 Mg.
- By Route of Administration: Oral and Nasogastric Tube.
- By Route of Application: Acute Coronary Syndrome, Heart Surgeries, Angioplasty, Stent Placement, and Coronary Artery Bypass Graft, among others.
- By End-user: Hospitals Clinics and Ambulatory Centers, among others.
- By Regions: Europe, North America, Asia Pacific, and the Rest-of-the-World.
Global Ticagrelor Market – Regional Analysis
North America leads the global Ticagrelor market with the largest market share. Heading with the rising geriatric population that is highly prone to degenerative diseases and prevalent chronic diseases, the region is estimated to retain its dominance throughout the forecast period. Additionally, the presence of a well-developed healthcare sector, alongside, the high per capita healthcare expenditures and well-spread awareness drive the regional market growth.
Growing markets in the US and Canada backed by the presence of prominent market players, positively impact the growth of the Ticagrelor market in the region. Furthermore, increasing diagnosis and therapeutics would support the market to create a significant revenue pocket during the assessment period (2017-2027).
The Ticagrelor market in the European region accounts for the second-largest market, globally. The rising patient population of strokes cardiovascular disorders and the introduction of advanced integrated treatment options are expected to boost the regional market growth.
Moreover, factors such as favourable government support for researches on antiplatelets, availability of advanced treatment facilities, and increasing healthcare expenditure, foster the growth of the market in the region. The UK, backed by its sizeable Ticagrelor market and Germany with its vast medical technology and pharmaceutical industry, contribute to the growth of the regional market, significantly.
The Asia Pacific Ticagrelor market is rapidly emerging as a promising market globally. Factors like increasing per capita disposable income and government initiatives to enhance the quality of healthcare drive the regional market growth. Moreover, the burgeoning pharmaceutical industry in this region is predominantly influencing the growth of the APAC Ticagrelor market.
Additionally, spreading awareness towards the disorder and the availability of novel treatment procedure to manage the condition influence the growth of the regional market, positively. Furthermore, the rising prevalence of cardiovascular diseases led by the changing lifestyles alongside, the continually rising healthcare expenditures and favourable government policies substantiate the market growth in the APAC region.
Global Ticagrelor Market – Competitive Analysis
Fiercely competitive, the Ticagrelor market appears to be fragmented due to the presence of many players. Large and small players alongside, the new entrants form a competitive landscape. They try to gain a substantial market share through strategic initiatives such as mergers acquisitions, expansion, collaboration, and product/ technology launch.
Industry, Innovation Related News
- September 02, 2019 –--- Strs Ohio (the US), a leading global institutional investor announced the acquisition of a new stake in Phase Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical company. PhaseBio focuses on the development and commercialization of novel therapies and drugs, such as a reversal agent for the antiplatelet drug ticagrelor. The institutional investor acquired 3,700 shares of the company’s stock, valued at approximately USD 48,000.
About US:
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
